Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Company Growth (employees)
Type
Public
HQ
Chandler, US
Founded
1998
Size (employees)
423 (est)-17%
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US

Key People at Insys Therapeutics

Michael L. Babich

Michael L. Babich

CEO
Andrew Long

Andrew Long

Chief Financial Officer
Larry Dillaha

Larry Dillaha

CMO

Insys Therapeutics Office Locations

Insys Therapeutics has an office in Chandler
Chandler, US (HQ)
444 S Ellis Rd

Insys Therapeutics Data and Metrics

Insys Therapeutics Financial Metrics

Insys Therapeutics's revenue was reported to be $36 m in Q1, 2017
USD

Revenue (Q1, 2017)

36 m

Gross profit (Q1, 2017)

31.3 m

Gross profit margin (Q1, 2017), %

87%

Net income (Q1, 2017)

(6.5 m)

EBIT (Q1, 2017)

(12.3 m)

Market capitalization (18-Aug-2017)

661.8 m

Cash (31-Mar-2017)

68.4 m
Insys Therapeutics's current market capitalization is $661.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

99.3 m222.1 m330.8 m242.3 m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7 m28.9 m25.4 m

Gross profit

86.6 m199.5 m301.9 m216.9 m

Gross profit Margin, %

87%90%91%90%

Sales and marketing expense

69.7 m

R&D expense

73.9 m

General and administrative expense

62.1 m

Operating expense total

54.1 m135.5 m209.5 m209.6 m

EBIT

32.6 m64 m92.4 m7.3 m

EBIT margin, %

33%29%28%3%

Interest expense

928 k

Interest income

502 k1 m

Pre tax profit

31.6 m93 m8.4 m

Income tax expense

8.8 m

Net Income

40.4 m38 m58.5 m7.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

55.7 m58.3 m70.8 m77.6 m91.3 m62 m67.1 m55.2 m36 m

Cost of goods sold

6.6 m5.4 m6.4 m8.3 m7.7 m4.6 m6.3 m4.7 m4.6 m

Gross profit

49.1 m52.9 m64.4 m69.3 m83.6 m57.3 m60.8 m50.5 m31.3 m

Gross profit Margin, %

88%91%91%89%92%93%91%92%87%

Sales and marketing expense

14.1 m15.1 m20.9 m22 m19.2 m19.8 m19.7 m16.7 m15.7 m

R&D expense

9.2 m7 m10.6 m17.8 m12.3 m20.5 m22.9 m16.5 m12.9 m

General and administrative expense

10.7 m10.8 m21.2 m15.3 m13.7 m14.7 m13.9 m17.7 m15 m

Operating expense total

34 m32.9 m52.8 m55.1 m45.2 m55 m56.5 m50.8 m43.6 m

EBIT

15.2 m20 m11.6 m12 m39.1 m2.3 m4.3 m(328 k)(12.3 m)

EBIT margin, %

27%34%16%15%43%4%6%(1%)(34%)

Interest income

26 k43 k125 k105 k128 k225 k256 k281 k435 k

Pre tax profit

15.2 m20.1 m11.8 m12.1 m39.2 m2.6 m4.6 m(47 k)(11.9 m)

Income tax expense

5.7 m8.6 m3.7 m4.8 m13.1 m131 k240 k(237 k)(5.3 m)

Net Income

9.5 m11.5 m8 m7.3 m26.1 m2.4 m4.4 m190 k(6.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

45.4 m58.1 m79.5 m104.6 m

Inventories

14.5 m34.8 m41.7 m21.7 m

Current Assets

82.2 m151 m253.2 m231 m

PP&E

10.1 m38.4 m43.2 m

Total Assets

100.6 m215.1 m351.2 m356.1 m

Accounts Payable

16.6 m27.5 m36.4 m27.4 m

Current Liabilities

21.1 m45.7 m88.9 m78.6 m

Total Liabilities

86.5 m

Common Stock

354 k719 k719 k

Additional Paid-in Capital

168.5 m216.4 m245.7 m256.5 m

Retained Earnings

(89 m)(51.1 m)7.4 m12.7 m

Total Equity

79.5 m165.7 m253.7 m269.6 m

Financial Leverage

1.3 x1.3 x1.4 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

46.1 m47.4 m70.1 m74 m94 m73.8 m69.3 m93.5 m68.4 m

Inventories

24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m21.3 m

Current Assets

102.2 m128.7 m182.1 m198.2 m236.6 m220.8 m234 m235.2 m196.9 m

PP&E

17.4 m24.1 m33.8 m35.5 m36.7 m39.6 m39.9 m41.3 m46 m

Total Assets

149.9 m188.2 m247.2 m275 m314.1 m325 m338 m353.1 m337.6 m

Accounts Payable

15.1 m24.5 m36.6 m30.6 m24.2 m25.7 m22.2 m17.5 m28.2 m

Current Liabilities

28.3 m43.2 m58.8 m67.3 m69.6 m67.5 m71.3 m76.6 m61.9 m

Common Stock

345 k348 k357 k718 k720 k715 k716 k718 k721 k

Additional Paid-in Capital

193.1 m205.1 m227.3 m239 m245.5 m239.4 m244.3 m253.8 m261.2 m

Retained Earnings

(71.9 m)(60.4 m)(43 m)(35.7 m)(9.6 m)9.9 m14.2 m14.4 m6.1 m

Total Equity

121.5 m145 m184.6 m204 m236.6 m250 m259.3 m268.8 m267.8 m

Financial Leverage

1.2 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

40.4 m58.5 m7.6 m

Depreciation and Amortization

1.8 m2.5 m5.3 m6.2 m

Accounts Receivable

(13 m)(10 m)(22 m)26.6 m

Inventories

(7.4 m)(20 m)(6.9 m)15 m

Cash From Operating Activities

24.2 m49.7 m100.9 m58.9 m

Purchases of PP&E

(5.1 m)(22.2 m)(13.8 m)(10.6 m)

Cash From Investing Activities

(5.5 m)(69.9 m)(88.7 m)(22 m)

Cash From Financing Activities

26.3 m32.9 m9.3 m(11.7 m)

Income Taxes Paid

991 k3 m15.4 m10.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

9.5 m11.5 m8 m7.3 m26.1 m2.4 m4.4 m190 k(6.5 m)

Inventories

24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m

Accounts Payable

15.1 m24.5 m36.6 m30.6 m24.2 m25.7 m22.2 m17.5 m28.2 m
USDY, 2017

Revenue/Employee

77.1 k

Financial Leverage

1.3 x

Insys Therapeutics Market Value History

Insys Therapeutics Median Salaries

Source: 24 public H-1B filings from Insys Therapeutics

Traffic Overview of Insys Therapeutics

Insys Therapeutics News and Updates

Feds Arrest 6 Former Insys Execs for Allegedly Bribing Doctors

DOJ says doctors received kickbacks to prescribe an incredibly potent painkiller.

Insys Therapeutics Company Life and Culture

You may also be interested in